Issuance of License seen as the most significant commercial event in the biotechnology Company’s development of spider silk based materials

ANN ARBOR, Mich., – May 1, 2018 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, is very happy to announce today the positive result of its five years of working with the Vietnamese government at both the central and provincial levels: The Company has been issued its long awaited Enterprise Registration Certificate (ERC) required to begin its operations in Vietnam.

“These licenses to operate in a traditional silk producing region are the most substantial milestones for Kraig Labs commercial development since the creation of our first spider silk transgenics,” said Kraig Labs Founder and CEO, Kim Thompson. “Our teams in the U.S.A. and in Vietnam have been working closely with officials in Quang Nam province and with central government ministries to bring this long standing vision to reality.”

The Company’s advanced silk production platform was designed specifically to fit within and utilize existing silk industry infrastructure. The Company’s systems were designed that way in order to provide what the Company believes to be a significant and nearly insurmountable competitive advantage. “Our work to obtain these approvals has been driven by our goal of producing recombinant spider silk on a large scale, which can only be achieved by harnessing the opportunities presented by existing large scale silk production infrastructure,” stated Thompson.

The Company has already proven through its contract with the U.S. Army that its spider silk technology can be scaled quickly and efficiently, moving from the laboratories of the University of Notre Dame and into its own research and production facilities. We are now on a path to scale our product to much greater levels, by harnessing existing silk production infrastructure with the capacity to match the demand for our spider silk materials.

“Today’s announcement is more than just a major milestone for the Company, it’s a revolutionary step in the commercialization of spider silk,” said Jon Rice, Kraig Labs’ COO. “More than five years of hard work, meetings, and extensive legal and regulatory paperwork, have gone into securing these approvals and licenses. We now stand ready to change an entire industry.”

“This is a historic moment for Kraig Labs and for all of our shareholders who have taken part in this journey with us. Our shareholders know how much time, effort and resources have been expended to reach this goal and for the Company to walk through this exciting threshold,” Thompson concluded.

Today’s announcement follows closely on the heels of last week’s announcement of the formation of the Company’s Vietnamese subsidiary Prodigy Textiles Co., Ltd., and the receipt of that subsidiary’s Investment Registration Certificate (IRC). Having been issued both its IRC and with today’s announcement, its Enterprise Registration Certificate (ERC), Prodigy Textiles Co., Ltd. is preparing to begin operation. The issuance of these critical licenses mark a major milestone for Kraig Biocraft Laboratories and the commercialization of spider silk.

Kraig considers its new wholly owned subsidiary, Prodigy Textiles Co., Ltd., to be its spider silk production arm. Vietnam has been the focus of the Company’s efforts to launch commercial scale production of recombinant spider silk, due to the country’s existing silk production infrastructure. Kraig estimates that it can produce its recombinant spider silk at prices similar to mundane silk, giving the Company a tremendous competitive advantage.

The Company is now preparing for the grand opening of its subsidiary operations in Quang Nam province, Vietnam. Management is preparing to hire staff for the new facilities and is prepping the first allotment of transgenic silkworms to ship from its U.S. research headquarters.

To view the most recent edition of Kraig’s Spider Sense quarterly newsletter and/or to sign up for Company alerts, please go to www.KraigLabs.com/newsletter

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implicatio

ns for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include 

descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com

New subsidiary created as Company’s production arm for large scale Spider Silk production

ANN ARBOR, Mich., – April 24, 2018 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announces today that it has received approval for the establishment of its new Vietnamese subsidiary, Prodigy Textiles Co. Ltd.  The Company is happy to announce it has received, from Vietnam, its official investment registration certificate for the new subsidiary.  The establishment of the Company’s first subsidiary is seen by management as a major milestone toward its long term goal of establishing large scale spider silk production. 

Vietnam has been the focus of the Company’s efforts to launch commercial scale production of recombinant spider silk, due to the country’s existing silk production infrastructure.  The Company’s advanced silk production platform was designed specifically to fit within and utilize existing silk industry infrastructure.  The Company’s systems were designed that way in order to provide what its founder and CEO, Kim Thompson, believes to be a significant and nearly insurmountable competitive advantage.

While the establishment of Prodigy Textiles Co. Ltd. is viewed by the Company as a major milestone toward commercialization and large scale production, establishing production in Vietnam requires a separate government issued enterprise registration certificate. 

“What a great moment for Kraig Labs and the entire Spider Silk industry.  We anticipate that our new subsidiary in Vietnam will open the doors and pave the way for spider silk production and our commercialization efforts,” said Thompson.  “I want to thank our COO, Jon Rice, and our exceptional team of professional consultants who have worked tirelessly to make the founding of this production arm of our Company a reality.”

To view the most recent edition of Kraig’s Spider Sense quarterly newsletter and/or to sign up for Company alerts, please go to www.KraigLabs.com/newsletter   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

As the Company prepares for commercialization of its engineered spider silk, Kraig Labs shares information on the developing industry.

ANN ARBOR, Mich., –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, releases the following statement regarding developments in the growing Spider Silk Industry.

Spider silk’s toughness is said to be 10 times greater than steel and some silks are nearly as elastic as rubber.  According to some studies, spider silks can be two to three times tougher than even Kevlar, which explains why so many researchers have targeted this fiber for protective clothing and body armor applications, as well as other potential military applications including technical undergarments and more practical ropes.

Numerous scientific studies have highlighted spider silk’s many intrinsic qualities and why it may be the ideal fiber for a slew of applications.  For example, spider silk’s maximal resilience, or ability to absorb energy, makes it one of the sturdiest materials on a weight-to-weight basis. These properties could make spider silk the foundation for many lightweight products, including air bags, seat belts, flexible bridge suspension cables, sports helmets and motor vehicle panels.

Additionally, studies have shown spider silk to be antimicrobial, biocompatible, hypoallergenic and totally biodegradable. Spider silk is a biomaterial that could be the platform on which to develop many medical technologies, like better bandages, elastic ligaments, and artificial tendons and even biodegradable water bottles.

Concurrent to Kraig Labs positioning for commercial production of its advanced fibers, many independent scientific studies have shown great promise in a vast array of potential spider silk applications.  The Company would like to congratulate all efforts that advance spider silk technologies.  A few recent examples of that work are provided below.  Each of these reports is entirely unaffiliated with Kraig Labs, and we therefore have not and cannot authenticate any specific conclusions. 

• Extremely thin sutures for eye or nerve surgery http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0016990
• Biosensors https://phys.org/news/2012-10-eco-friendly-optics-spider-silk-talents.html  
• Hearing aids https://www.healthyhearing.com/report/52826-Spider-silk-could-offer-breakthrough-in-hearing-aid-microphones
• Air quality improvement https://www.sciencedaily.com/releases/2014/01/140114113339.htm
• Artificial skin https://www.livescience.com/15443-artificial-skin-spun-spider-silk.html

As noted in the linked report, just the chronic wounds, such as bedsores in hospitalized patients, afflict 6.5 million in the United States for an estimated $25 billion annually. The Company believes that the various scientific discoveries in the spider silk space were instrumental in seeing over $300 million in funding flow into spider silk platform development over the past few years. One of the Company’s current competitors is approaching $196 million in aggregate funding, including $106 million in 2017, potentially valuing that pre-production technology at more than $1 billion dollars, when applying a commonly used valuation formula.

http://www.kblbinvestors.com/new-breakthroughs/

“As Kraig Labs prepares to transition into commercial production, we plan to expand our R&D focus and, given the tremendous interest in spider silk, we believe that we will have many great opportunities to grow newly discovered application into new business lines with strong growth potential. As we initiate a process to explore further scientific alliances our objective is to help maximize the future value of Kraig Labs,” stated Kim Thompson, Kraig Labs’ CEO and Founder. 

Industrial applications may include flexible bridge suspension cables, better fishing nets and unrippable paper. Spider silk’s well-balanced combination of strength and elasticity may even be combined with graphene to create the next generation of metamaterials.

Under funding from the US Army Research Office and the National Science Foundation professor Xinwei Wang at Iowa State University published a paper on Spider silks ability to conduct heat as well or better than most materials, including very good conductors such as silicon, aluminum and pure iron.  That discovery reportedly “opens a door for soft materials to be another option for thermal conductivity tuning,” as stated by professor Wang in the above reference publication.  This may inspire better semiconductors and lead to the creation of flexible, heat-dissipating parts for electronics, microchips, better clothes for hot weather, bandages that don’t trap heat and many other everyday applications.

By designing a high performance fiber, based on a proven efficient and ecologically friendly production platform, the Company’s objective is to target a broad cross section of applications in the $160 billion (projected) technical fibers market and the budding smart textile markets.  The Company intends to also target the mundane markets, like active wear and the $5 billion raw silk fibers market, which have tighter pricing elasticity.

 “It’s very exciting to think that we may be positioned to focus our efforts and resources on participating in advancing some of the many researchers who approach us to employ our fibers for various potential mechanical applications and we’re looking forward to collaborations that could open a new realm of possibilities for our technology,” said Jon Rice, Kraig Labs’ COO.

To view the most recent edition of Kraig’s Spider Sense quarterly newsletter and/or to sign up for Company alerts, please go to www.KraigLabs.com/newsletter   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,”

“foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

New larger Hybrid Cocoons provide production excitement

ANN ARBOR, Mich., –  April 11, 2018 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announces follow up to its recently introduced new Hybrid Spider Silk Silkworm Cocoons, which were produced at the Company’s new research and development facility.

Development for the new hybrid was completed in-house, at Kraig Labs R&D facility using its Dragon Silk colony silkworms and a commercial mundane silkworm strain, which resulted in an estimated 100% increase in cocoon weight, compared to the cocoons that the Company was producing just four months ago in Indiana.

The Company understood that silkworms have been producing mundane silk for thousands of years and, that by employing the existing sericulture infrastructure, as well as expertise and traditions, it can cost effectively scale-up its transgenic spider silk silkworm production. According to Kraig Labs’ data, the Company should be able to commercialize some of the toughest natural fibers for almost the same cost as normal every day silk.

Eight countries produce the majority of world’s silk today, all of which have the resources and expertise to bring the Company’s fibers to market through mass production.  These countries have the potential to play a part in expanding Kraig Labs’ production footprint.

The Company believes that the new hybrid cocoons, along with its first recombinant spider silk producing silkworms and the development of Dragon Silk, are among the biggest sericulture breakthroughs in modern history.  As such, it’s important that the host countries respect Intellectual Property.  This is one of the reasons that Kraig Labs is looking at the potential of launching production in Vietnam.

“When I originally set out on the journey to mass produce spider silk, I knew that there were multiple production platform options.  Each of the obvious production platforms had serious shortcomings, including most importantly, an inability to produce spider silk at an acceptable price point.  I focused on inserting silkworms with the relevant gene sequence because silkworms have proven to be economically efficient and commercially viable natural silk producers.  In my opinion, silkworm remains the only economically viable platform,” stated Kim Thompson, Kraig Labs’ CEO and Founder.  “Kraig Labs’ R&D facility is a powerful tool to help us achieve optimum fiber and business performance,” Thompson concluded.

The activity in our industry has recently increased dramatically; most notably, multiple companies reportedly having raised over $300 million in combined funding to produce synthetic silks, which require chemicals and other steps to create their product. While these companies have interesting technological approaches, we believe, they lack the cost effectiveness of our silkworm based technology.  In our opinion, those approaches have no real way to commercialize spider silk in a way that takes advantage of the properties that make spider silk special, or at price points that are competitive with mundane silk.

 “Our production optimization initiatives are vital steps in the drive towards cost structure optimization and our new cocoons have shown us that even the most efficient fiber making process that exists in the world today, can be improved. A 100% increase in cocoon size from our existing products without any increased labor is a substantial win for our shareholders,” said Jon Rice, Kraig Labs’ COO.

We have posted our cost analysis on the existing market, and believe it confirms our ability to lead in this space, and why our excitement is growing to begin our first large scale production.  For further details concerning Kraig Labs’ cost advantages and comparative analysis, please go to www.kraiglabs.com/comparison

The Company is updating production plans and will update the shareholders and other interested parties when appropriate.

To view the most recent edition of Kraig’s Spider Sense quarterly newsletter and/or to sign up for Company alerts, please go to www.KraigLabs.com/newsletter   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,”

“foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – April 3, 2018- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, today announced that the Company has successfully produced the first recombinant spider silk cocoons from the new line of hybrid transgenic silkworms recently created at its Michigan production and research facility.  This new hybrid line was created by combining one of the Company’s best performing recombinant spider silk lines with a commercial strain, resulting in the largest cocoons in the Company’s history. 

The first generation cocoons from this hybrid cross have exceeded the Company’s expectations with some cocoons nearly twice as large as the original spider silk line cocoons.  These larger cocoons reduce operating and handling costs throughout the production process and yield longer silk threads.  Mechanical performance testing of this new hybrid spider silk line is expected to begin shortly. 

“Crossing our recombinant spider silk silkworm lines with larger traditional silkworm lines is an element of both our research roadmap and commercialization plans.  The results we’ve seen from this first crossing confirm the benefits of those strategies,” said Jon Rice, COO.  “The size of these new hybrids is beyond what we expected in a first generation hybrid and we are very interested to see how performance testing results compare to the original silkworm lines.  We anticipate creating many additional hybrids, over the coming quarters, combining the performance of our spider silk lines with these larger commercial strains.  We expect these efforts will increase our production efficiency and lower our cost to produce recombinant spider silk.”

About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

The Company identifies and implements plan to improve its recombinant spider silk

ANN ARBOR, Mich., – January 25, 2018- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, today announced that the Company has recently implemented an expanded material performance testing procedure for its recombinant spider silk technology. This procedure is part of the Company’s efforts to continuously improve its operations and products. 

With this new expanded testing, the Company has already identified variances in material properties for its transgenic silkworm lines, which fall outside of the Company’s target ranges.  This variance is believed to be the result of genetic drift within the Company’s silkworm strains. 

In response to this new discovery, the Company has implemented an intensive selective breeding program to leverage the results of the newly established testing procedure.  The Company has also begun a cross breeding project to reinvigorate its transgenic lines with commercial silk genetics.  Combined, the expanded testing and selective breeding efforts are designed to allow the Company to more tightly control silk properties, while at the same time, creating the necessary genetic diversity within each line.  

The increased throughput and capacity for material testing, enabled by the Company’s new facilities and new testing protocol, is expected to identify even more opportunities for material and process improvements over the coming quarters.  The Company intends to use these discoveries to improve its operations and its products. 

“The expanded capacity for testing, which resulted from our decision to insource a major portion of our research operations, has already proven its significant value to the Company,” said Jon Rice, COO. “The results from performance testing, under the new testing protocol, have already been translated into an action plan.  The ability to quickly translate those results into an action plan is a great example of the value in consolidating our research and production into a single facility.  The efforts already underway to improve our testing and selective breeding should result in an improved process and more uniform final product.  Our plan is to improve quality back to our target range before spooling up for mass production.  This could cause a delay in commercialization if the other parts of our commercialization plan fall into place earlier. Uniform materials, improved quality control, and minimizing the performance variance will play an important part in our work to commercialize spider silk.  The information gained from this program will continue to inform our drive for continuous improvement.”

To view the most recent edition of Kraig’s Spider Sense quarterly newsletter and/or to sign up for Company alerts, please go to www.KraigLabs.com/newsletter.

About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (w), a fully reporting biotechnology company, is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – January 19, 2018- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, today announced that the Company succeeded in creating a new hybrid transgenic silkworm at its Michigan production facility.  This is the first hybrid silkworm created at the new Michigan facility, which recently opened in October of 2017. 

This is the first new hybrid line developed in conjunction with the Company’s US Army contract and is the next step in its program to expand its commercial recombinant spider silk offerings.  The new recombinant spider silk strain combines properties from one of the Company’s best performing transgenics with a large commercial silkworm line, to produce larger cocoons and even stronger silk.

“Creating our first hybrid in the new facility is a great moment for the Company,” said Jon Rice, COO. “The transgenic line that we used, as the base for this new hybrid, has been under development for some time.  We are very eager to review the test results for this new line, as they come in.   The opportunity to soon analyze its capabilities, once transformed into a commercial line, are very exciting.”

To view the most recent edition of Kraig’s Spider Sense quarterly newsletter and/or to sign up for Company alerts, please go to www.KraigLabs.com/newsletter.

About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (w), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – January 8, 2018- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, today announced that the US ARMY has fully funded its ongoing contract to develop new recombinant spider silk fibers. The additional funding, just over $420,000, brings the total allocated funding on the contract to $1.02 million. This second phase of the Company’s contract with the US ARMY, valued at $921,000, began in July of 2017 and is focused exclusively on the development of new spider silk fibers. The Company is currently utilizing multiple approaches to create these transgenics, with performance that surpasses the original Dragon SilkTM that was produced for the baseline contract.

“The US ARMY’s choice to exercise the base contracts option period and to dramatically increase the total contract value gave us the ability to boost our research and development efforts substantially,” said Jon Rice, COO. “Under this expanded scope we are directed to develop new transgenics, with greater strength and toughness than anything we’ve ever seen before. With the allocation of the remaining contract funding, the US ARMY has now obligated all of the dollars committed in that contract award.”

About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (w), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com